Skip to main content
Figure 5 | Journal of Hematology & Oncology

Figure 5

From: SNS-032 inhibits mTORC1/mTORC2 activity in acute myeloid leukemia cells and has synergistic activity with perifosine against Akt

Figure 5

SNS-032 reduces expression of IGF-1R and PI3K isoform p110δ and IGF-1 does not reverse SNS-032-mediated cellular inhibition. (A) HL-60 and KG-1 cells were cultured with increasing concentrations of SNS-032. At 6 h after treatment, cells were harvested and lysed, and expression of IGF-1R and PI3K isoforms p110α and p110δ was determined by Western blot analysis. Actin was used as protein loading control. (B) The levels of IGF-1R and PIK3CD mRNA was determined after 6 hours-exposure of SNS-032 by real-time quantitative RT-PCR, and expressed as relative levels compared with controls. (C) Three AML cell lines were treated with 100 nM SNS-032 for 24 h, with or without IGF-1 (100 ng/mL) preincubation for 3 h, and then cell viability was examined by an MTT assay. All values represent the mean of experiments in triplicate; bar, ± s.d. (D) HL-60 cells were treated with SNS-032, or combined with IGF-1. Protein expression of IGF-1R, total and phosphorylated forms of mTOR was analyzed by Western blot. Actin levels were used as loading control.

Back to article page